|
|
|
|
Vol. 57, Issue 4, 769-777, April 2000
Oncology Division, Department of Medicine, and the Cancer Biology
Program, Stanford University School of Medicine, Stanford, California
(G.K.C., N.J.L., G.E.D., B.I.S.); and Oncology Research Group, Novartis
Pharmaceutical Corporation, East Hanover, New Jersey (D.C.)
In this study, we further characterize a mutant P-glycoprotein (P-gp)
that has a deletion of Phe335 and is resistant to
inhibition by cyclosporins. Photoaffinity labeling with
[3H]cyclosporine and [3H]azidopine revealed
markedly decreased binding to the mutant P-gp compared with wild-type
P-gp. Expression of the mutant P-gp in multidrug-resistant variant cell
line MES-SA/DxP (DxP) cells was associated with a 2-fold higher basal
ATPase activity relative to multidrug-resistant cell line MES-SA/Dx5
(Dx5) cells with wild-type P-gp. Cyclosporine inhibited ATPase activity
in both cell types, whereas the cyclosporin D analog valspodar (PSC
833), vinblastine, and dactinomycin stimulated ATPase activity in Dx5
but not in mutant DxP cells. Moreover, the cell lines differed in their
responses to verapamil, which produced greater stimulation of ATPase in Dx5 than DxP cells. Verapamil significantly reversed the
[3H]daunorubicin accumulation defect in wild-type Dx5
cells, but it had no significant effect on
[3H]daunorubicin accumulation in the mutant DxP cells.
Verapamil was not transported by cells expressing either mutant or
wild-type P-gp. Vanadate trapping of azido-ATP was markedly impaired in mutant P-gp. In conclusion, our data demonstrate that
Phe335 of transmembrane 6 is an important amino acid
residue for the formation of cyclosporine and azidopine drug-binding
site(s). Phe335 also plays a role in the coupling of
verapamil binding and modulation of daunorubicin intracellular
accumulation in wild-type P-gp. In addition, Phe335 in
transmembrane 6 may play a role in coupling drug binding to ATPase
activity. The deletion of Phe335 results in a significant
increase in the basal ATPase activity with a concomitant decrease in
its ability to trap ATP and transport some P-gp substrates.
This article has been cited by other articles:
![]() |
K. F. K. Ejendal and C. A. Hrycyna Differential Sensitivities of the Human ATP-Binding Cassette Transporters ABCG2 and P-Glycoprotein to Cyclosporin A Mol. Pharmacol., March 1, 2005; 67(3): 902 - 911. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Gruol, J. Bernd, A. E. Phippard, I. Ojima, and R. J. Bernacki The Use of a Novel Taxane-Based P-Glycoprotein Inhibitor to Identify Mutations That Alter the Interaction of the Protein with Paclitaxel Mol. Pharmacol., July 1, 2001; 60(1): 104 - 113. [Abstract] [Full Text] |
||||